5 Stock Setups Where Wall Street Sees the Most Upside Right Now
The article lists five “upside” stock calls from Wall Street. JPMorgan initiated CECO Environmental (CECO) with a $130 target, citing AI data center demand and Thermon. It also targets PRM at $50. Goldman upgraded Toast (TOST) to Buy at $36. BofA raised Ligand (LGND) target to $388. Revolution Medicines (RVMD) reported Phase 3 pancreatic cancer results for daraxonrasib, with median OS 13.2 vs 6.7 months.
How this was made
The 30-second read
Why it matters
Trader focus is on catalyst quality: RVMD’s Phase 3 readout and planned FDA submission are primary; the other four are primarily analyst initiation/upgrade calls with targets and thesis drivers (Thermon acquisition, monopoly procurement, XOMA Royalty deal, and Toast’s AI agent cycle).
Market read
Provides decision-relevant catalysts for RVMD and actionable sell-side target changes for CECO, PRM, LGND, and TOST, but it is not a single-company earnings or regulatory filing for most names.
What to watch
For CECO and PRM, execution and procurement timing matter more than the monopoly framing; for RVMD, the market will scrutinize FDA review path, confirmatory endpoints, and competitive landscape beyond the headline OS result.
Background
The article is a Wall Street “upside” roundup that highlights five names with analyst target changes and, for RVMD, newly reported Phase 3 efficacy data.
Ticker impact
JPMorgan initiated coverage with a $130 target, citing the Thermon acquisition and AI data-center power buildout demand.
Bullish bias toward continued multiple expansion if bookings and guidance hold.
The article provides specific analyst target and company guidance changes, but it is still framed as a “setups” list rather than a fresh print.
JPMorgan initiated coverage at Overweight with a $50 target, calling Perimeter Solutions a niche fire-retardant monopoly with a portable M&A playbook.
Potential upside skew if government purchasing and contract pricing remain resilient.
The key new element is the analyst initiation and target, not a new contract or regulatory action.
Bank of America raised its target to $388, citing Ligand’s pending $39-per-share acquisition of XOMA Royalty closing in Q3 2026.
Support for a rerating if deal progress and royalty growth remain on track.
The article includes deal timing and target change, but no new regulatory or financing event is disclosed.
Goldman upgraded Toast to Buy with a $36 target after the stock fell 34%, pointing to a reset and an AI agent product cycle.
Near-term upside bias if investors accept the margin and ARR trajectory implied by the upgrade.
Upgrade and target are concrete, but the article is not a same-day earnings release; it is a “setup” roundup.
Revolution Medicines reported Phase 3 data for daraxonrasib, with median overall survival 13.2 months vs 6.7 months for chemotherapy and p<0.0001.
Elevated volatility and upside skew as the market prices probability of approval and launch readiness.
The article discloses primary Phase 3 efficacy results plus cash runway and planned FDA filing, which are decision-relevant.
Market effects
AI data-center power buildout read-through supports industrial equipment and electrification supply chains; oncology efficacy read-through can lift sentiment for RAS(ON) pathway peers.
US-focused catalysts, including US Defense Logistics Agency and California forestry contracts referenced for PRM.
Global AI infrastructure capex and oncology drug development sentiment can influence cross-border biotech and industrial equipment risk appetite.
Counterpoint
These are “setups” driven heavily by sell-side targets and narratives; clinical and bookings outcomes can diverge from the implied upside, especially for turnaround stories.
Key entities
- companyCECO Environmental
Industrial equipment supplier tied to AI data-center power buildout; JPMorgan cites Thermon acquisition and raised FY26 outlook.
- companyPerimeter Solutions
Fire retardant supplier positioned as a US-scale monopoly; JPMorgan initiation emphasizes M&A portability and government purchasing.
- companyLigand Pharmaceuticals
Royalty-stream holder; BofA highlights XOMA Royalty acquisition and raised target.
- companyToast
Restaurant software and payments platform; Goldman upgrade frames a reset and AI agent product cycle.
- companyRevolution Medicines
Oncology biotech; Phase 3 daraxonrasib results show OS benefit vs chemotherapy and plans for FDA submission.
